Lockheed's Q3 Beat Lifts Stock, But Missile Execution Questions Persist

What happened

Lockheed Martin shares jumped 9.6% after the company reported a Q3 earnings beat and record backlog, according to Zacks Investment Research. The article focuses on defense ETFs with significant LMT exposure, suggesting the stock move makes these ETFs attractive, but it offers no segment-level detail. The latest DeepValue master report, written after Q2 2026 results, maintained a WAIT rating with key concerns about funded PAC-3 awards, MFC margin sustainability, and ongoing Aeronautics charges. Without confirmation that Q3 earnings resolved these issues, the share price increase appears driven by headline momentum rather than fundamental improvement. At the implied post-jump price of approximately $638, LMT trades above the master report's base-case implied value of $605, leaving minimal margin of safety.

Implication

Current holders may consider trimming if the price exceeds $650, as the master report advised trimming above that level. New buyers should wait for confirmation that Q3 details include funded PAC-3 awards, sustained MFC margins above 14%, and no fresh F-16 or C-130 charges. The record backlog is positive but driven heavily by THAAD and missile programs, which may not provide broad company-wide operating leverage. ETF inflows may provide short-term price support, but they do not change the underlying execution risks. Watch the next quarterly filing for evidence that the earnings beat was not merely timing-related and that missile demand is converting into clean, high-quality earnings.

Thesis delta

The thesis shifts from cautious to even more cautious because the post-earnings price increase has likely pushed the stock further above fair value without confirming the key prerequisites for a bull case. The master report's WAIT rating becomes more appropriate as the stock moves away from an attractive entry point. Upside now requires funded PAC-3 awards and sustained MFC margin expansion, neither of which are confirmed by the news released.